purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation sny earnings call period ending december image source motley fool sanofi sny q earnings callfeb etcontents prepared remark question answer call participant prepared remark eva schaeferjansen good morning good afternoon good evening everyone thank joining u review sanofis fourthquarter fullyear result followed qa session usual find slide call investor page website sanoficom moving slide would like remind information presented call contains forwardlooking statement involve known unknown risk uncertainty factor may cause actual result differ materially refer form f document file sec also document denregistrement universel description risk factor please advance slide speaker call today paul hudson chief executive officer houman ashrafian global head rd jeanbaptiste de chatillon chief financial officer global business unit head brian foard thomas triomphe olivier charmeil julie van ongevalle operator instruction would like turn call paulshould invest sanofi right buy stock sanofi consider motley fool stock advisor analyst team identified believe best stock investor buy sanofi one stock made cut could produce monster return coming year stock advisor provides investor easytofollow blueprint success including guidance building portfolio regular update analyst two new stock pick month stock advisor service tripled return sp since see stock stock advisor return january paul hudson chief executive officer well thank eva thanks everyone joining call today discus q highlight going start updating another announcement made morning francoisxavier roger join sanofi taking role cfo effective april st pleased welcome sanofi accomplished widely recognized finance executive proven track record accelerated value creation fact may met already either role nestle past takeda take finance organization significantly modernized jbs leadership past five year jb instrumental successful execution first chapter playtowin strategy creating growth opportunity ahead u jb helm finance team consistently delivered healthy topline growth last year significant boi margin improvement billion euro cost efficiency reinvested behind growth driver pipeline also worked closely olivier julie simplification genmed standalone consumer health business two critical project delivered significant value company shareholder many may aware jbs longstanding personal commitment charity work decided devote next stage career leading renowned frenchbased foundation certain positive impact jb continue people life would like take opportunity warmly thank dedication leadership great partner dare say friend rest executive committee thank jb marked pivotal year sanofi became development driven techpowered biopharma company core growth driver specialty care vaccine continue deliver main driver remains dupixent continued deliver stellar performance approved indication across geography dupixent added billion euro top line billion euro constant exchange rate also mark successful year vaccine business launch beyfortus real moment strategy execution general medicine core asset kept growing gbu sale lower overall due net price erosion continue actively manage portfolio divest nonstrategic product moving consumer healthcare business delivered growth driven priority brand recently acquired qunol excellent strategic fit business know last quarter announced intention separate chc business following earlier decision create standalone unit fully unlock value also allow u better focus time resource pureplay biopharma company process reviewing potential separation scenario still believe path likely maximize shareholder value would capital market transaction create public listed company headquartered paris subject market condition course separation could achieved earliest q nutshell strong performance dupixent key launch offset anticipated impact loss exclusivity aubagio last major loe remainder decade excluding aubagio underlying sale growth business fabulous underlying growth trajectory moving slide perfectly demonstrates ability laser focused come launch excellence turn sanofi launch engine beyfortus altuviiio tzield generated sale million euro far exceeding expectation beyfortus faced unprecedented demand already able protect almost million baby first season clearly confirm importance allinfant protection strategy altuviiio capturing switch united state hemophilia market tzield created great excitement among clinician first therapy delay onset type diabetes three transformational medicine join aggrading number sanofis new product launch since new product generated billion euro across different fast growing therapeutic area launch add top line next dupixent many year keeping mind face major loe rest decade remember rd day december th believe everything take become leading immunology company addition recent pharma launch record number medicine pipeline potential blockbuster status including three potential billion euro peak sale expect launch exceed billion euro sale time dupixent keep onceinacareer life changing medicine continuing deliver low doubledigit sale growth cagr finally growth driver vaccine continue power u forward leading position rsv flu pediatric combination vaccine franchise bringing billion euro sale moving slide excited dupixents potential become first biologic treat copd partner regeneron making rapid progress submitting application approval europe yous also china let u certainly forget itepekimab anti il monoclonal antibody hold additional potential copd recent phase result asset highly encouraging two large phase trial nearing completion enrollment pivotal result expected together dupixent itepekimab potential address large copd population limited overlap believe two medicine combined peak sale potential greater billion euro copd let share key priority year number one keep laser focused bestinclass launch working closely partner astrazeneca regulatory authority increase supply beyfortus meet tremendous demand altuviiio continue capture patient share yous hemophilia market drive geographic expansion promising start japan tzield increase effort around patient screening enrollment support program course launch preparation dupixent copd well underway number two keep moving swiftly pipeline priority expect tolebrutinib phase data relapsed remitting secondary progressive m around midyear initiate planned trial many promising immunology neurology vaccine asset finally cost reallocation announced month ago new set efficiency initiative across biopharma business free operational resource support accelerated rd investment unlock value creation opportunity continue target saving billion euro end fund innovation growth sum year investment science inaudible pipeline position u strong eps revamp let conclude highlighting commitment fight climate change making clear progress trajectory reach carbon neutrality exemplified leveraging renewable electricity expanding ecocar fleet reminder ambition vetted sbti science based target initiative attended cop dubai last december push elevate need stronger collaboration across healthcare system active contributor sustainable market initiative privilege lead patient care pathway working group focus effort reduce carbon emission health system improving health outcome patient well hand houman head rd share insight rd priority milestone year houmanhouman ashrafian global head research development thank paul discussed december rd day sanofi delivered unprecedented cadence positive news important data readout last year across major project blockbuster potential increasing investment rd intend fully capitalize growth opportunity ahead u prioritizing pipeline asset meaningful growth potential extending opportunity successfully launch medicine year look forward several important regulatory milestone readout pipeline already mentioned paul expect regulatory milestone dupixent copd pivotal readout tolebrutinib relapsing m secondary progressive m well rilzabrutinib itp amlitelimab rilzabrutinib excited learn outcome important phase result asthma later year separately preparing submit recent positive phase result sarclisa first line transplant ineligible myeloma patient fda approval expect pivotal data subcutaneous administration year end would bring additional upside sanofi large market seeking convenient treatment option recall rd day highlighted ambition increase number phase project across immunology neurology vaccine next two year significant number pivotal trial already started dose first patient including first amlitelimab phase trial ad phase trial frexalimab relapsing m secondary progressive m progressing well evolving right pace expect project phase turning phase fortunate initiate significant number project presented rd day one example frexalimab type diabetes started study assessing different dos route administration sticking strategy combining strong innovative science opportunity address patient major unmet need also see proof point progress rd productivity moving major asset oral tnfr signaling inhibitor lunsekimig midstage portfolio providing promising solution multiple indication believe increased rd investment pivotal phase program key phase trial offer longterm return benefit patient shareholder essence playtowin strategy moving slide provided granular concrete sense area changing sanofi rd recent investor event yield first talked big investment dispassionate data driven evaluation pipeline investing winning late stage asset underwrite longterm growth sanofi accordingly drive late stage opportunity launching multiple phase trial parallel need increase investment longterm opportunity u drive real growth value shareholder disciplined way second theme must earn right going deliver portfolio focus across breadth platform site ta continue right win oncology focused way uniquely uniquely positioned win immunology information deep provenance immunology selffulfilling prophecy lead developing better immunology drug also research immunology finally pipeline sustainability although made good progress improve rd productivity focus greater quality step leveraging inhouse research external innovation slide great example external innovation let take one minute talk recently announced acquisition inhibrx fit perfectly rare disease portfolio overlapping immune mediated respiratory franchise underlined rd day continue drive successful rare franchise keep eye open immunemediated disease periphery close deal add inbrx portfolio recumbent human alpha antitrypsin fc fusion protein treatment alpha antitrypsin deficiency inherited rare disease lung liver causing progressive tissue deterioration phase trial showed strong data bestinclass profile thanks sustaining normal aat level aiming better compliance due potential monthly dosing regimen current standard care plasmaderived aat leaving patient sufficiently effective wellvalidated treatment across rare disease therapy committed patient aatd next readout expected potential launch potentially rapid approval following fda fast track designation granted last may blockbuster potential behind asset predicated use existing patient anticipated use increased number de novo patient could benefit treatment great pleasure hand gbu head go respective business performance brianbrian foard global business unit head specialty care thank much houman taking closer look specialty care delivered doubledigit growth quarter supported outstanding performance dupixent paul mentioned earlier strong demand exceptional medicine across approved indication geography continues core driver specialty care rare disease business another important contributor quarter strong growth across pompe gaucher fabry product highlight unique expertise identifying patient ability drive demand new patient approval rollout nexvizyme new standard care pompe zempizyme asmd continue successful global market rare blood disease pleased continued strong uptake altuviiio another exciting launch specialty care going update little bit insight brand recent performance minute believe continued doubledigit growth specialty care particularly impressive backdrop generic competition aubagio sanofis last meaningful loe rest decade generic version aubagio entered key market including europe september almost billion euro sale continue navigate impact generic erosion including particularly high base comparison aubagio first quarter moving next slide dupixent sale reached almost billion euro fourth quarter alone highlighted slide fullyear sale driven continuous robust growth yous exyous geography almost seven year initial yous launch atopic dermatitis achieved maintained leadership position nbrxs across five approved indication confident deliver around billion euro sale previously guided remain excited outlook brand outstanding commercial success expect copd become another important growth pillar time paul discussed earlier significant regulatory progress achieved copd across key market plan launch yous later year quick reminder lefthand side chart notice similar seen previous year common specialty biologics q growth usually reflects impact higher seasonal patient copay assistance program utilization associated annual resetting insurance deductible beginning year expect similar effect weigh reported sale first quarter turning next slide saw strong momentum altuviiio fourth quarter altuviiio become top choice switch hemophilia market capturing switch really driven brand differentiated efficacy profile importantly two every three switch come competitive product including estimated nonfactor hemlibra addition gain number yous patient also saw geographic expansion promising launch japan late last year launch date seen broad uptake yous many hcps even stated intent increase depth prescribing provides u another encouraging indicator launch progress pas thomasthomas triomphe global business unit head vaccine thank brian growing year year q vaccine sale reached billion euro driven strong uptake beyfortus impressive launch elaborate next slide flu sanofi continues market leader driven differentiated product portfolio represent majority total flu sale line q earnings call comment approximately h flu sale reported fourth quarter generating sale reduction yearonyear saw lower premiumization rate season increased level competition yous market finally pleased q performance pph franchise benefited favorable public order pattern yous despite vaxelis sale recorded net sale q vaxelis become yous pediatric primary service leader continues gain share pentavalent vaccine next slide focused rsv franchise starting left see launch beyfortus yous set new record term routine pediatric immunization uptake compared similar pediatric vaccine launch rotavirus meningococcal conjugate vaccine average adoption rate six month launch beyfortus performance illustrates successful implementation first broad infant recommendation yous france spain encouraged strong real world clinical data generated spain look forward rolling beyfortus broadly beyond infant segment respiratory syncytial virus also significant burden toddler older adult developing vaccine specifically targeted two group glad report vaccine candidate making good progress toddler live live attenuated intranasal rsv vaccine candidate received eu prime designation december following yous fast track designation designation recognize potential vaccine candidate address significant unmet medical need communicated vaccine day phase start quarter older adult initiated last november phase clinical trial mrna rsv hmpv vaccine highlighted believe combo vaccine real potential first class medical value compared rsv standalone vaccine provide compelling case recommending body value combo already recognized yous fda granted fast track designation october phase result positive phase trial planned start end year overall thrilled phenomenal progress rsv team made last six month building foundation sanofi become leader rsv franchise let hand call olivierolivier charmeil global business unit head general medicine thank thomas general medicine sale four quarter showed slight decrease billion euro core asset grew driven plavix toujeo rezurock praluent partially offset lower sale mozobil due generic competition started yous july sale rezurock yous continued grow strongly driven increasing patient number well improved adherence rate toujeo q sale delivered doubledigit growth driven china largely offset lower sale yous due lower average net price sale noncore asset decreased mainly driven lower lantus sale yous continued affected negative channel mix well lower inventory tradein anticipation list high figure full year genmed sale decreased due exceptional impact yous launch decline along vbp impact lantus sale china mentioned tzield continued gradual uptake type diabetes november launched wellreceived national screening campaign yous increase awareness encourage screening atrisk individual result screening grew driven endocrinologist patient infused end year number patient infused grew q versus q despite yearend holiday season full result product study newly diagnosed stage type diabetes patient shared ispad congress interaction fda ema ongoing handing juliejulie van ongevalle global business unit head consumer healthcare thank olivier firstly would like start update separation chc business previously announced could happen q year earliest making solid progress journey full business autonomy continue enhance internal talent pool selective hire key area service agreement put place establishing digital infrastructure hit ground running day one regarding performance q mark th consecutive quarter growth sale driven primarily price excluding divestment acquisition q growth around qunol acquisition closed end september drove growth physical mental wellness category may recall qunol product focus healthy aging u glad qunol part chc business giving u fast growing platform compete important yous vms market last quarter introduced priority brand represent total net sale growth past three year q full year brand major growth driver resulted growth full year good growth across category largest category digestive wellness continues perform strongly doubledigit growth market share gain would like give background one brand category dulcolax dulcolax world number one nonprescriptive laxative important note onethird world population suffer constipation yet nearly half still seek treatment laxative make attractive substantial market opportunity dulcolax growing faster market past three year executing repeatable model growth three main driver one change focus marketing consumer moving positioning purely medical functional solution emotional communication breaking taboo constipation educating dulcolax work naturally body second launching innovative consumer friendly gentle format chewables driven category penetration last least working healthcare professional resulting strong endorsement simple reputable amount growth confident dulcolax continue help consumer gain market share handing jeanbaptiste cfojeanbaptiste de chatillon chief financial officer thank thank julie heard quarter driven double digit growth specialty care vaccine dupixent rare disease key driver specialty care vaccine sale grew general medicine sale decline decelerated chc reported another quarter growth looking q pl slide gross margin expansion driven improved product mix strong contribution covid vaccine revenue last quarter rd expense grew cer mainly reflecting continued progress vaccine pipeline mainly driven mrna development program quarter also start recording share phase development cost related recently announced collaboration jnj potential firstinclass expec vaccine boi margin decreased percentage point mainly due decrease capital gain related product disposal compared quarter last year eps q turning fullyear group pl slide recorded improvement gross margin almost percentage point due covid vaccinerelated sale revenue product mix also contributed gross margin expansion partially offset lower aubagio sale due generic competition lower net price launch u operating expense grew roughly line sale business operating margin remained stable constant exchange rate eps year grew line fullyear guidance slide board proposing annual dividend euro represents increase last year progressive dividend policy remains important part capital allocation policy launched different efficiency initiative presented q objective reallocate billion euro saving focus program first bestinclass potential reallocating resource growth driver strategic therapeutic area also leverage procurement generate additional saving lastly modernize commercial delivery optimizing country setup expanding hub strategy increase centralization refocusing rd critical site technology platform slide providing outlook full year q fullyear sale expect dupixent reach billion euro vaccine franchise grow midsingledigit driven ongoing launch beyfortus aubagio loe continue impact mainly h planned genmed divestments lower top line around million euro fullyear pl expect gross margin decrease slightly due absence covid sale revenue opex expected grow due roughly million euro stepup rd sga expense expected remain stable finally announced q etr increase due implementation dillard dynamic q differ overall year mainly due high base effect vaccine genmed aubagio top dupixent sale annual stepup yous copay already mentioned brian similarly pl side remind high level capital gain generated q advancing final slide slide expect fullyear business eps decline low single digit cer excluding impact tax rate change fullyear business eps would roughly stable foreign exchange see negative currency impact minus minus based january average exchange rate year resetting company longterm value creation expect strong eps rebound let u open call qaeva schaeferjansen operator instruction first question come luisa hector berenberg luisaluisa hector berenberg capital market analyst hi hear meeva schaeferjansen luisa hear usluisa hector berenberg capital market analyst yes hear mepaul hudson chief executive officer yeahluisa hector berenberg capital market analyst great thank maybe question would beyfortus get bit color manufacturing ability meet demand year whether would anticipate perhaps demand second season vaccination able show given sort high vaccination rate country show emergency room entry rsv gone like sort data support use vaccine would first question obviously would like extend thanks everyone jb conversation year thank jb congratulation move guess question would word advice would pas better paul hudson chief executive officer well thank luisa think gracious say jb give moment two think word advice thomas come beyfortus perhaps open could share data galicia guide might look like know publishing supply beyfortus thomas triomphe global business unit head vaccine great point indeed seen q result happy strong beyfortus launch q q million euro sale q start think showing implementation allinfant protection program highly feasible go well record uptake six month back question first supply element discussed previously clearly sanofi astrazeneca working hard extend manufacturing network packaging site filling site always going precise today always first need qualify line make registered different regulatory authority work ongoing right order able completely would say debottleneck supply full supply season season see increase supply think share together expectation reach blockbuster status beyfortus precise bit early ramp supply progress get regulatory authority come back second point extremely important luisa really thank asking end day reason industry really make sure impact term clinical efficacy actually baby go hospitalization go er really ask everyone guy moment look galicia data referenced slide look know well end season spain data important unlike yous france partial patient coverage rate year actual spain data country coverage rate see show extremely impressive data see see hospitalization rate year baby le eight month age ie eligible beyfortus hospitalization rate extremely low baby one year age ie susceptible normal rsv infection protected actually high rsv season rsv disease receive beyfortus go hospitalization provide data end season obviouslypaul hudson chief executive officer second seasonthomas triomphe global business unit head vaccine second season product indicated first rsv season except small population infant either specific heart condition specific lung condition usually depending population newborn population beyfortus getting second season retargeting first season interestingly seen rsv toddler intranasal vaccine targeting bring beyfortus inaudible available protectedpaul hudson chief executive officer thank thomas congrats amazing launch jb time reflect advice going give certainly given plenty advice together sure short somethingjeanbaptiste de chatillon chief financial officer short first thank much luisa bit lot emotion today course financials company better count pipeline science innovation hand add arrogance advice ready make ready make bring fruition develop decided course paul ga know paul hudson chief executive officer found opening comment think worked well management team jb particularly well pushed pretty hard honest time necessary try much discipline possible making sure take advantage opportunity think comment pipeline extraordinarily wellmade made sacrifice position squander think saying right think interested course would announced costsaving program think need know aligned jbs wish comment go full ahead reallocation blink one reason excited work francoisxavier pick wellrun machine intensity think important people understand squander jb ok next questioneva schaeferjansen next question jo walton ubs joe joe hear u ubs team ok let u move come back jo walton ubs analyst hear meeva schaeferjansen yesjo walton ubs analyst sorry question consumer side please looking progress rxotc switch trial tamiflu cialis thinking whether visible point separation going forward secondly timing copd launch know filed yet know time frame review priority review voucher could assume would use important launch many thankspaul hudson chief executive officer ok thanks jo great connected julie update switchesjulie van ongevalle global business unit head consumer healthcare sure know already launched cialis together uk since last call also received approval norway ireland yous conducting certain study support strategy lift clinical hold study complete looking forward discussing result fda coming quarter hope gain alignment next step tamiflu update timepaul hudson chief executive officer yeah think julie mean much conversation fda think fair say expected u done done find whether enough gone others find certainly progress cialis know whether want go brian next copd question voucher assumption around launchbrian foard global business unit head specialty care first foremost thank much question really really excited next potential opportunity may recall back august fda quite unique move granted u breakthrough designation time first trial since read second trial trial positive exacerbation filed announced filed december th waiting regulatory feedback feedback agency speak anticipating said earlier pre setup launching still determined whether prior review seepaul hudson chief executive officer ok thank anything else houman ok good thanks jo next questioneva schaeferjansen next question tim anderson wolfetim anderson wolfe research analyst thank yep couple question beyfortus could describe longerterm opportunity par geography meaning yous versus exyous one product likely sale coming yous often different product second question view potential competition merck product clesrovimab phase data back part year implies launch also monoclonal first impression product based know todaypaul hudson chief executive officer right thomas breadth launch thought thatthomas triomphe global business unit head vaccine risk disappointing tim might give spreadsheet detailed forecast geography coming year course encouraged q launch year said everything confident supply issue looking broadly term geography noticed got registration beyfortus china expect registration beyfortus japan coming month progressively start launch china japan end really going per named allinfant protection progressive rollout geography china seen multiple vaccine take time progressive solution opportunity look mid long term could significant year sale twothirds yous onethird eu might perfect presentation short term rsv everywhere want go geography progressively one step time competition aspect two player know well one already licensed maternal immunization think clear fundamental difference beyfortus maternal vaccine beyfortus designed protect infant maternal vaccine design back previous question luisa please look galicia result coverage rate early infant impact hospitalization impressive year one product merck product phase comment data phase thing say believe bar set term standard care look profile beyfortus efficacy impressive per disease data also term safety talking fragile part population newborn safety profile nirsevimab pristine think right let u look phase result med productpaul hudson chief executive officer ok thank thanks thomas thanks tim next questioneva schaeferjansen next question peter welford jefferiespeter welford jefferies analyst hi thanks taking question going speak first beyfortus comment phasing made comment first quarter supply think time delivering dos still yous wrong sort carry anticipate beyfortus sale dip rise winter season guess plan southern hemisphere also considering middle three quarter curious specific near million given yous alone across region far beyfortus launched second question one jb pl increase operating income quarter referenced release something litigation related payment wonder much could quantify bit led significant increase roi quarter perhaps relative expectation thank youpaul hudson chief executive officer thomas maybe thought q share phasing distribution almost million dos put already schedulethomas triomphe global business unit head vaccine first first question rsv disease course seasonal disease therefore see cadence wish nh country sale q q south hemisphere country sale q q due supply limitation fact progress process sorry ramping supply would expect q q key quarter beyfortus see communicated ago small sale delivery product january looking couple country maybe south hemisphere country significant sale perspective really q q q back point mentioned precise approximately million dos includes season ie includes january february really total ie yous plus europepaul hudson chief executive officer ok jb endjeanbaptiste de chatillon chief financial officer yeah thank wel realize forex visible impact pl effectively specifically ten million provision pas q scattered topic nothing particularpaul hudson chief executive officer ok good thank next questioneva schaeferjansen next question richard vosser jp morganrichard vosser jpmorgan chase company analyst hi thanks taking question question inbrx inhibrx product think inhibrx highlighting first readout end could talk difference timing second half timing whether still see initial data ahead maybe final data question flu please obviously flu vaccine hesitancy hearing increased competition think referenced back situation sort overcapacity flu market outside high dose outside old adult expect price pressure going forward think flu season going forward thanks muchpaul hudson chief executive officer ok good maybe houman want commenthouman ashrafian global head research development yeah richard thank question short answer term operational outcome expect result comment look forward seeing result element bring molecule deal closedpaul hudson chief executive officer ok good thomas getting plenty airtime today flu maybe comment high dose differentiation piece thought could mean pricing standard dosethomas triomphe global business unit head vaccine important question richard would say continuation observed past two year situation flu market overall definitely ample supply versus demand accelerated decrease flu vcr past couple year especially north america various reason think one point mind though linked fact moderate flu season term disease know well year get softer three four season lower suddenly year come back first big hit saying right western europe increase flu disease yous immune overall situation course anticipated came earlier differentiated flu vaccine two differentiated flu vaccine portfolio significant data significant data showing impact term improved protection versus infection compared standard dose none competitor call protection beyond flu brought success differentiated vaccine represents still h flu sale summarize would say overall standard dose price pressure expectation correct seeing still ample room trajectory differentiated flu vaccine zydus efluelda inaudiblepaul hudson chief executive officer ok thank next question pleaseeva schaeferjansen next question graham parry bank americagraham parry bank america merrill lynch analyst great thanks taking question first question altuviiio think quite lot patient free drug second third quarter could give u update many patient actually free drug bridging program q would expect progress separately excuse inhibrx asset recall inhibrx indicated fda wanted data linking functional aat level going normal level sort clinical outcome sort precursor filing basis functional aat level accelerated review still agree clinical endpoint confirmatory trial could give u update think process data generated think clinical endpoint needed approval thank youpaul hudson chief executive officer thank graham brian altuviiiobrian foard global business unit head specialty care yep first foremost know day program quite helpful u seen patient go program get converted commercial really fantastic said going go previously patient gone program anticipate go probably stabilize somewhere around range coming yearspaul hudson chief executive officer thank brian houmanhouman ashrafian global head research development thanks question excellent question call asset yet beginning dig question fully appreciate ongoing discussion fda term say bioavailability bioequivalence native alphaantitrypsin right endpoint deep discussion fact even last week conversation alpha foundation patient group consider exactly move forward thanks question watch spacepaul hudson chief executive officer thank youeva schaeferjansen next question simon baker redburn simon ok maybe move next question simon baker redburn partner analyst hi hear sorryeva schaeferjansen yes goodsimon baker redburn partner analyst yeah hi thank sorry please provide color view potential ceacam target given recent tusamitamab ravtansine fader second one beyfortus seen strong uptake u group payer channel region strongly represented others adc thank youpaul hudson chief executive officer ok thank ceacam given tusamitamab data maybe thought different payload still valid targethouman ashrafian global head research development thanks question excellent question continue believe based precision medicine computational biology approach classical immunogenic chemistry ceacam highly specific highly expressed target density profile well suited adc approach call correctly previous molecule dm payload sadly provide high efficacy bar put order serve patient value believe number basic biological reason topo payload current molecule preclinical level also clinic show significant promise short answer remain optimistic ceacam adcspaul hudson chief executive officer thank beyfortus particular thomas triomphe global business unit head vaccine assume simon talking payout coverage u first significant part newborn coverage vfc program public part converge well private medical side thing check recently week ago already way way payor coverage u month see problem term payor coverage present might practitioner hcps course want go slowly want make sure reimbursed probably covered seen yous past week think something past confident youspaul hudson chief executive officer yeah build simon question course referenced yous maybe share enthusiasm seeing different country europethomas triomphe global business unit head vaccine definitely think know wellknown europe look plenty previous historical benchmark vaccine entry europe normally take year term progress recommending body reimbursement decision early stage seeing lot european country trying accelerate process order make sure beyfortus go earlier protectionpaul hudson chief executive officer thank thomas next questioneva schaeferjansen next question come david risinger leerinkdavid risinger leerink partner analyst yes thank much wanted say thank best luck jb two question paul please first provide color outlook spending growth also discus potential operating leverage beyond thanks muchpaul hudson chief executive officer thank david ok jbjeanbaptiste de chatillon chief financial officer yeah thank much yes try question pretty simple lay enjoy steady growth u many year ahead loe front u heard paul mentioning underlying growth enjoying neutralize impact aubagio pretty easy see going enjoy growth said would increase bit crush increased million euro rd program still running like tolebrutinib copd large phase multiple phase program program end oncology ii reallocation plus effort term cost reallocation fully kick flat opex versus clear topline growth trigger leverage looking beyond beyond done taken decision going developing pipeline free break ceiling growth rate profitability sanofi experimented past year see go said going enjoy long run growth clear opportunity create value go loe dupixent billion euro billion euro billion euro billion euro billion euro billion euro asset billion euro billion euro peak sale potential seen rd day take already seen also relentless adding portfolio inorganically inhibrxpaul hudson chief executive officer thank jb next question pleaseeva schaeferjansen next question gary steventon exane bnp gary gary hear uspaul hudson chief executive officer maybe move next phoneeva schaeferjansen ok come back gary let u move rajesh kumar hsbc rajesh ok gary online think also question written box going read florent cespedes societe generale question chc one question could elaborate dynamic europe decline q u organic growth still possible raise price yous another question driver challenge confident consensus eps growth paul hudson chief executive officer ok good right well julie europe dynamic yous price flexibility jb come back eps rebound julie van ongevalle global business unit head consumer healthcare ok q think maybe q think three factor important notice impacted growth versus consensus first divestments noncore brand part plan simplify portfolio coming end program still impact performance yous explained first softer market dynamic also underperformance brand action improve performance brand happening speak especially allergy pain category addition obviously qunol strengthening position deliver future growth yous europe strong position think strength overall business driven leadership brand leadership position respective market still lot potential grow thanks mainly penetration well innovation help price room pricing room pricing obviously le room pricing past still see category overall little bit resilient especially otc category resilient many consumer categoriespaul hudson chief executive officer thank julie jb maybe last commentjeanbaptiste de chatillon chief financial officer strong rebound coming pretty naturally pretty mechanically yeah confidence highpaul hudson chief executive officer thank jb wise word thank everybody thanks connected today everybody played part positioned well blockbuster ahead u launch performance keep delivering wait readout celebrate success launch thank mucheva schaeferjansen operator signoff duration minutescall participantseva schaeferjansenpaul hudson chief executive officerhouman ashrafian global head research developmentbrian foard global business unit head specialty carethomas triomphe global business unit head vaccinesolivier charmeil global business unit head general medicinesjulie van ongevalle global business unit head consumer healthcarejeanbaptiste de chatillon chief financial officerluisa hector berenberg capital market analystjo walton ubs analysttim anderson wolfe research analystpeter welford jefferies analystrichard vosser jpmorgan chase company analystgraham parry bank america merrill lynch analystsimon baker redburn partner analystdavid risinger leerink partner analyst sny analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy